SCHEDULE 13G: FMR LLC and Abigail P. Johnson Disclose 10.7% Stake in Stoke Therapeutics Inc.
Beneficial Ownership Report
FMR LLC and its affiliates, including Abigail P. Johnson, have reported a beneficial ownership of 10.7% of Stoke Therapeutics Inc.'s common stock as of May 30, 2025, held in the ordinary course of business.
Summary
- FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating beneficial ownership of common stock in STOKE THERAPEUTICS INC.
- As of May 30, 2025, the aggregate amount beneficially owned by FMR LLC and Abigail P. Johnson is 5,859,011 shares.
- This represents 10.7% of the total outstanding common stock of STOKE THERAPEUTICS INC.
- FMR LLC holds sole voting power over 5,851,537 shares and sole dispositive power over 5,859,011 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- Fidelity Institutional Asset Management Trust Company and Fidelity Management & Research Company LLC are identified as relevant entities within FMR LLC that beneficially own shares, with Fidelity Management & Research Company LLC owning 5% or greater.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive. While a 13G is a factual filing, a significant stake by a major institutional investor like FMR LLC can be interpreted as a vote of confidence in the company, which is generally positive for market perception. There are no negative implications within the filing itself.
Positives
- A significant institutional investor, FMR LLC, has taken a substantial 10.7% stake in Stoke Therapeutics Inc., potentially signaling confidence in the company's long-term prospects.
- The filing indicates the stake was acquired in the ordinary course of business, suggesting a passive investment rather than an activist intent.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding the issuer's future performance or strategic direction, as it is solely a beneficial ownership report.
Industry Context
This filing indicates a significant investment by a major asset manager, FMR LLC, in a biotechnology company, Stoke Therapeutics Inc. Such investments are common in the biotech sector, where institutional capital plays a crucial role in funding research, development, and commercialization efforts. A substantial stake by a reputable firm like FMR LLC can be viewed positively by the market, suggesting a belief in the company's long-term potential within the competitive pharmaceutical and biotechnology landscape.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence stock price positively due to perceived validation from a major fund.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC and its direct and indirect subsidiaries, authorizing Stephanie J. Brown to sign on their behalf. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC where the Power of Attorney effective January 3, 2023, was incorporated by reference. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson, authorizing Stephanie J. Brown to sign on her behalf. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC where the Power of Attorney effective January 26, 2023, was incorporated by reference. |
| 2025-05-30 | Date of event which required the filing of this statement, indicating the beneficial ownership percentage was established on this date. |
| 2025-06-05 | Date the Schedule 13G was signed and filed by FMR LLC and Abigail P. Johnson. |
Keywords
STOKE THERAPEUTICS INC, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.